In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roche to promote Actemra (tocilizumab, used in chronic arthritis) and Syndyma (bevacizumab, an anti-cancer drug used in multiple indications) for the Indian ...
Read more: Cipla's U-turn: Happily ever after?